RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+9.11%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$7.02B
AUM Growth
+$7.02B
(+7.4%)
Cap. Flow
+$119M
Cap. Flow
% of AUM
1.69%
Top 10 Holdings %
Top 10 Hldgs %
49.95%
Holding
78
New
10
Increased
26
Reduced
8
Closed
5
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$133M |
| 2 |
Zai Lab
ZLAB
|
$83.9M |
| 3 |
Quest Diagnostics
DGX
|
$72M |
| 4 |
Abbott
ABT
|
$60.4M |
| 5 |
Guardant Health
GH
|
$44.6M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
$147M |
| 2 |
Akero Therapeutics
AKRO
|
$104M |
| 3 |
Globus Medical
GMED
|
$82.4M |
| 4 |
RAPT Therapeutics
RAPT
|
$82.3M |
| 5 |
Alkermes
ALKS
|
$63M |
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Quest Diagnostics
DGX
$20.3B
| $89.8M | 1.28% |
500,000
+401,003
| +405% | +$72M |
|
27
uniQure
QURE
$933M
| $71.9M | 1.02% |
5,158,231
+892,803
| +21% | +$12.4M |
|
28
GH Research
GHRS
$837M
| $67.5M | 0.96% |
5,540,457
+40,688
| +0.7% | +$496K |
|
29
UroGen Pharma
URGN
$900M
| $62.3M | 0.89% |
4,543,895
+709,101
| +18% | +$9.71M |
|
30
Ultragenyx Pharmaceutical
RARE
$2.89B
| $62.1M | 0.88% |
1,707,402
| – | – |
|
|
31
Abbott
ABT
$231B
| $60.4M | 0.86% |
+444,000
| New | +$60.4M |
|
32
Stoke Therapeutics
STOK
$1.07B
| $58.2M | 0.83% |
5,123,525
| – | – |
|
33
Taysha Gene Therapies
TSHA
$797M
| $57.8M | 0.82% |
25,021,584
+6,233,718
| +33% | +$14.4M |
|
34
Spyre Therapeutics
SYRE
$996M
| $54.2M | 0.77% |
3,621,996
| – | – |
|
|
BBNX
35
Beta Bionics, Inc. Common Stock
BBNX
$819M
| $48M | 0.68% |
3,299,191
-679
| -0% | -$9.89K |
|
36
GE HealthCare
GEHC
$33.7B
| $46.4M | 0.66% |
626,000
+106,000
| +20% | +$7.85M |
|
|
37
Guardant Health
GH
$8.41B
| $44.6M | 0.63% |
+856,501
| New | +$44.6M |
|
38
CG Oncology
CGON
$2.04B
| $44.2M | 0.63% |
1,701,216
| – | – |
|
39
Rocket Pharmaceuticals
RCKT
$354M
| $43.3M | 0.62% |
17,687,772
| – | – |
|
40
Immatics
IMTX
$649M
| $37.5M | 0.53% |
6,970,152
+60,642
| +0.9% | +$326K |
|
41
Soleno Therapeutics
SLNO
$3.57B
| $35.6M | 0.51% |
+424,408
| New | +$35.6M |
|
42
MoonLake Immunotherapeutics
MLTX
$3.54B
| $35M | 0.5% |
+741,090
| New | +$35M |
|
|
TEM
43
Tempus AI, Inc. Class A Common Stock
TEM
$13.6B
| $25.4M | 0.36% |
400,000
| – | – |
|
|
LENZ
44
LENZ Therapeutics
LENZ
$1.12B
| $25.3M | 0.36% |
863,389
| – | – |
|
|
CMPS
45
Compass Pathways
CMPS
$434M
| $23M | 0.33% |
8,221,929
+2,683,761
| +48% | +$7.51M |
|
46
Orchestra BioMed
OBIO
$147M
| $22.3M | 0.32% |
8,306,062
+99,900
| +1% | +$268K |
|
|
ORKA
47
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $21.8M | 0.31% |
1,945,649
| – | – |
|
48
Neurogene
NGNE
$264M
| $20.4M | 0.29% |
1,362,456
+13,800
| +1% | +$206K |
|
|
CNTA
49
Centessa Pharmaceuticals
CNTA
$2.25B
| $20.1M | 0.29% |
1,529,836
+1,479,836
| +2,960% | +$19.4M |
|
50
89bio
ETNB
$1.34B
| $19.3M | 0.28% |
1,967,527
| – | – |
|